8 with traverse with respect to Group 5, claim 29. Applicants respectfully request that claim 29, which is directed to a β_2AR genome anthology, be rejoined with Group 1. As described in the specification, β_2AR genome anthologies are collections of β_2AR isogenes (see p. 12, lines 15-25), which are compositions comprised of nucleic acids. Since the claims in Group 1 are also directed to isogenes and compositions comprising nucleic acids, Applicants respectfully assert that claim 29 is directed to the same class of subject matter and should be considered part of Group 1.

This amendment cancels claims that were not elected or traversed by Applicants and Applicants reserve the right to pursue the non-elected subject matter in a subsequent divisional application(s). SEQ ID NOs:19-30, which were added to the Sequence Listing by the above amendment, correspond to the β_2AR isogenes defined by haplotypes 1-12 shown in Table 5 on p. 36. Each SEQ ID NO contains the examined region of SEQ ID NO:1 as described in Example 1 on p. 33 except for having a different combination of nucleotides at the set of polymorphic sites defining each of the twelve β_2AR haplotypes in Table 5 (see p. 5, lines 8-9, p. 11, lines 17-18 and lines 28-30). A replacement written Sequence Listing and computer readable form with accompanying statements under CFR §1.821 (f) and (g) are attached hereto and submitted in compliance with CFR §1.825.

Claim 1 has been amended to focus the invention on isogenes of the β_2AR gene. Support for the amendment to claim 1 can be found in claim 2 as originally filed and in the specification as originally filed, specifically on p. 5, lines 8-9 and p. 11, lines 28-30. Support for the amendment to claim 7 can be found in the originally filed specification on p. 17, lines 8-14 and p. 19, lines 4-18. Support for the amendment to claim 8 can be found on p. 19, lines 1-7.

Applicants respectfully assert that new dependent claims 30-32 are directed to the elected subject matter of Group 1 and thus their entry is respectfully requested. Each of claims 30 and 31 comprise the DNA molecule of claim 3, which comprises the polynucleotide of claim 1. Support for these claims can be found on p.12, line 26 to p. 13, line 21. Claim 32 depends from claim 7, and is directed to specific nucleotide sequences for the genotyping oligonucleotides of claim 7. Support for this claim can be found on p.19, lines 12-29. Additional support for any of the amendments made herein may be found elsewhere throughout the specification as originally filed.

Upon entry of this amendment claims 1, 3-5, 7-8 and 29-32 will be pending and a prompt action on the merits is respectfully requested. Replacement pages for pages 44-47 of the specification showing a clean version of the pending claims is attached hereto.

It is believed that no additional fees are due, however if that is incorrect, Applicants hereby authorize you to debit deposit account 50-1293. Should any questions arise regarding this submission, please contact the undersigned agent at the phone number below.

Received from < > at 6/13/02 4:04:20 PM [Eastern Daylight Time]

Respectfully Submitted,

Date: 6/13/02

Reg. No. 47,562
Tel. No. 203-786-3473

Gisela M. Field

Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Received from < > at 6/13/02 4:04:20 PM [Eastern Daylight Time]